Burning Rock Biotech (BNR) EBITDA (2019 - 2026)

Burning Rock Biotech (BNR) has reported EBITDA for 8 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 59.62% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$9.5 million (up 70.96% YoY), while the FY2025 annual figure was -$8.5 million, up 81.92% from the prior year.
• EBITDA came in at -$3.0 million for Q1 2026 at Burning Rock Biotech, down from -$2.5 million in the prior quarter.
• The five-year high for EBITDA was -$1.4 million in Q2 2025, with the low at -$41.7 million in Q1 2022.
• Average EBITDA over 5 years is -$17.0 million, with a median of -$16.1 million recorded in 2023.
• Across the five-year window, EBITDA plunged 73.72% in 2022 and soared 90.58% in 2025, its largest moves.
• Year by year, EBITDA stood at -$32.2 million in 2022, then grew by 27.75% to -$23.3 million in 2023, then jumped by 55.68% to -$10.3 million in 2024, then soared by 75.84% to -$2.5 million in 2025, then dropped by 19.9% to -$3.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.0 million, -$2.5 million, and -$2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.